Study to Measure Impact of ProstaScint Imaging in Prostate Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 7
Volume 11
Issue 7

PRINCETON, New Jersey-Cytogen Corporation’s ProstaScint (capromab pendetide) is being evaluated in a phase I/II clinical study for its utility in helping guide intensity modulated radiation therapy (IMRT) for prostate cancer.

PRINCETON, New Jersey—Cytogen Corporation’s ProstaScint (capromabpendetide) is being evaluated in a phase I/II clinical study for its utility inhelping guide intensity modulated radiation therapy (IMRT) for prostate cancer. 

ProstaScint is a radiolabeled monoclonal antibody that targets prostate specificmembrane antigen. In the study, the specific areas of greatest tumor burdenwithin the prostate, identified by the ProstaScint image, will receive boosteddoses of radiation via IMRT.

Articles in this issue
Translational Research, Early Clinical Trials Support Xeloda/RT in GI Cancers
Capecitabine Research Points to New Combinations for Metastatic Breast Cancer
Good Activity for Capecitabine Confirmed in European Study
European Data Support Benefit of Capecitabine/Irinotecan Regimen in Advanced Colorectal Cancer Patients
Single-Agent Capecitabine May Benefit Elderly Colorectal Cancer Patients
Single-Agent Sequential Rx May Be Reasonable for Metastatic Breast Cancer
Intermittent R115777 Equally Effective but Better Tolerated in Breast Cancer Patients
Carboplatin/Vinorelbine/Capecitabine Active in Pretreated Metastatic Breast Cancer
Longer Survival With FOLFOX4 in Metastatic Colorectal Cancer Patients
Capecitabine/Vinorelbine Effective in Heavily Pretreated Patients
Oral Regimen of UFT/Leucovorin and Etoposide Shows Promising Results
Docetaxel/Capecitabine Bests Single-Agent Docetaxel in Metastatic Breast Cancer
COX-2 Inhibitor May Boost Capecitabine Response
Celecoxib Added to IFL Reduces Toxicity in Patients With Metastatic Colorectal Cancer
Irinotecan Every 2 Weeks With Capecitabine Is Well Tolerated

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Event-free survival benefit was observed among BCG-naïve patients with carcinoma in situ undergoing treatment with sasanlimab plus BCG.
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
Related Content
Olaparib/Radium-223 Combination Demonstrates Feasibility and Antitumor Activity in CRPC

Olaparib/Radium-223 Combination Demonstrates Feasibility and Antitumor Activity in CRPC

Tony Berberabe, MPH
June 4th 2025
Article

The combination of olaparib and radium-223 improved rPFS in castration-resistant prostate cancer without prior docetaxel treatment or with fewer than 20 bone metastases.

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Mike Lattanzi, MD;Damian N. Sorce, MD
June 5th 2025
Podcast

Experts weigh in on the practical applications of PSMA PET imaging

Results from the phase 3 ARANOTE trial demonstrated a statistically meaningful improvement to rPFS with darolutamide vs placebo.

FDA OKs Darolutamide in Metastatic Castration-Sensitive Prostate Cancer

Tim Cortese
June 3rd 2025
Article

Results from the phase 3 ARANOTE trial demonstrated a statistically meaningful improvement to rPFS with darolutamide vs placebo.

A Sneak Peek at 2025 ASCO From the GU Perspective

A Sneak Peek at 2025 ASCO From the GU Perspective

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
May 15th 2025
Podcast

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, highlight exciting trials in the genitourinary cancer space expected to be presented at 2025 ASCO.

Niraparib Plus Abiraterone/Prednisone Extends rPFS in HRR-Altered mCSPC

Niraparib Plus Abiraterone/Prednisone Extends rPFS in HRR-Altered mCSPC

Silas Inman
June 3rd 2025
Article

Niraparib plus abiraterone acetate and prednisone significantly reduced the risk of symptomatic progression in patients with BRCA-mutated metastatic castration-sensitive prostate cancer.

Efficacy and safety outcomes in the phase 3 CONTACT-03 study were consistent regardless of prior immunotherapy or tyrosine kinase inhibitor use.

Second-Line Cabozantinib Regimens Exhibit Efficacy in Advanced RCC

Roman Fabbricatore
June 2nd 2025
Article

Efficacy and safety outcomes in the phase 3 CONTACT-03 study were consistent regardless of patients' prior immunotherapy or tyrosine kinase inhibitor use.